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The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily.
CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic
C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular
dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating
both B cell receptor-dependent and independent signaling. CD19 functions as the dominant signaling component
of a multimolecular complex on the surface of mature B cells, alongside complement receptor CD21, and the
tetraspanin membrane protein CD81 (TAPA-1), as well as CD225. Through study of CD19 transgenic and knockout
mouse models, it becomes clear that CD19 plays a critical role in maintaining the balance between humoral,
antigen-induced response and tolerance induction. This review also summarized latest clinical development of
CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel
antibody-drug conjugate.Rituximab, the first monoclonal antibody against CD20
molecule, has revolutionized lymphoma therapy [1,2].
More monoclonal antibodies targeting different antigens
are being developed for lymphoma therapy [3]. CD19 is
specifically expressed in normal and neoplastic lymphoid
cells. This review summarizes the molecular structure
and functions of CD19 antigen as well as the clinical de-
velopment of CD19 monoclonal antibodies for lymph-
oma therapy.CD19 gene and antigen
The human CD19 antigen is a 95 kd transmembrane
glycoprotein belonging to the immunoglobulin (Ig)
superfamily [4,5]. It is encoded by the 7.41 kilobite cd19
gene located on the short arm of chromosome 16,
16p11.2 [6]. The gene contains 15 exons and codes for
the CD19 molecule with 556 amino acids (Figure 1).
There are more than one mRNA transcripts, though
only two transcript isoforms have been isolated in vivo
[5-7]. Structurally, the gene contains an unusually short
5'-untranslated region. The proximal cd19 promoter* Correspondence: delong_liu@nymc.edu
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reproduction in any medium, provided the orlacks a TATA box, and its major start sites are found
within 50 bp of the initiation codon [8].
CD19 is classified as a type I transmembrane protein,
with a single transmembrane domain, a cytoplasmic
C-terminus, and extracellular N-terminus. No significant
homology exists between CD19 and other known proteins
[9]. The extracellular element contains two C2-type Ig-like
domains divided by a smaller potential disulfide linked
non-Ig-like domain, as well as N-linked carbohydrate
addition sites (Figure 2). The highly conserved cytoplasmic
domain consists of 242 amino acids with nine tyrosine
residues near the C-terminus [9-11]. Multiple studies have
come to suggest that the biologic functions of CD19 are
dependent on three cytoplasmic tyrosine residues – Y391,
Y482 and Y513. Experiments have shown that substitution
of phenylalanine for tyrosine at two of the positions, Y482
and Y513, leads to inhibited phosphorylation of the other
seven tyrosines [12-14].
Kinetics of CD19 expression
CD19 was first identified as the B4 antigen of human B
lymphocytes through the use of anti-B4 monoclonal
antibody (mAb) against CD19. It is specifically expressed
in normal and neoplastic B cells, as well as follicular
dendritic cells [9,11,15]. During B cell lymphopoiesis,
the surface expression of CD19 first takes place aroundtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and





















Figure 1 CD19 molecular structure. CD19 is a type I one-pass transmembrane protein. The two extracellular C2 Ig-like domains are separated
by a small helical non-Ig domain with possible disulfide links. The highly conserved, 242 amino acid cytoplasmic domain includes multiple
tyrosine residues. Three key tyrosine residues are shown with their associated signaling kinases and molecules.
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During this process, Pax5 is required for the normal ex-
pression of CD19. This was proven by the fact that
lymphoid progenitors in Pax5 knockout mice arrest at
the pro-B cell stage. The surface density of CD19 is






Figure 2 CD19 associated signaling complex. Antigen-C3d complexes c
BCR-dependent fashion. The CD19 complex includes complement receptormaturation, until the loss of expression during terminal
plasma cell differentiation [9,11]. CD19 expression in
mature B cells are 3-fold higher than that found in im-
mature B cells, with slightly higher expression in B1 cells
than in B2 (conventional B) cells [11,12]. CD19 is one of





an engage the CD19/21 complex in both a BCR-independent or
CD21, which binds C3d-modified antigen.
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ation to plasma cells.
Physiological function
CD19 is critically involved in establishing intrinsic B cell
signaling thresholds through modulating both B cell
receptor (BCR)-dependent and independent signaling
[16,17]. It plays roles in the antigen-independent devel-
opment as well as the immunoglobulin-induced activa-
tion of B cells. CD19 is thus critical for the body to
mount an optimal immune response. CD19 works in
complex with the BCR and other surface molecules to
allow both direct and indirect recruitment and binding
of various down-stream protein kinases [6,18]. The pro-
tein kinases that interact with the CD19 complex include
those belonging to the Src family (Lyn, Fyn), Ras family,
Abl, Btk, adapter molecules (Vav, Grb2), and PI3K [9].
More recently, it has been recognized that CD19 is
required for optimal MHC class II-mediated signaling,
through its modulation of tyrosine phosphorylation and
Akt kinase signaling [19].
CD19 functions as the dominant signaling component
of a multimolecular complex on the surface of mature B
cells, alongside complement receptor CD21 (CD2), and
the tetraspanin membrane protein CD81 (TAPA-1), as
well as CD225 [9,13,18,20] (Figure 2). The CD19 com-
plex functions to decrease the threshold for receptor-
dependent signaling through modulating both intrinsic
and receptor-induced signals [11,12,18]. CD19 acts as a
critical co-receptor for BCR signal transduction [13,21].
As BCR signaling requires protein tyrosine kinase (PTK)
activation, CD19 recruits and amplifies the activation of
Src-family protein tyrosine kinases such as Lyn and Fyn
[9,13,22]. Upon BCR activation, CD19 also enhances
BCR-induced signaling crucial for B cell expansion,
through recruitment and activation of PI3K and down-
stream Akt kinases [23].
The CD19/CD21 complex is also capable of, independ-
ent of the BCR, reacting and binding to activated
complement fragment C3d. This complex subsequently
translocates into membrane “lipid rafts” domains, where
tyrosine phosphorylated CD19 can then interact with
co-localized kinases in the membrane to modulate BCR
signaling [24]. Normally, more CD19 is found associated
with CD21 than in complex with BCR, and a dramatic
increase in B-cell activation results from the simultan-
eous binding of surface antigen by B-cell Ig and of C3d
by CD21. Studies also showed that CD19 does not
require CD21 for signal transduction, and CD19/21
complex signaling is induced by the binding of C3d to
CD21 [13,14].
CD81 functions as a part of the tetraspanin web as
well as a chaperone protein. It provides docking sites for
molecules involved in various signal transductionpathways, and is important for the expression of CD19.
CD19 expression in B cells of CD81−/− mice were found
to be ~30–50% of that in wild type (WT) mice, while ex-
pression of CD21 and the BCR were at their respective
WT levels [25,26]. CD19/CD38 have been shown to co-
localize in lipid rafts and physically interact with another
surface antigen receptor, CD38, in mice B cell. The two
receptors have been shown to be a part of the B cell
signaling complex [24,25]. In vivo, CD81-deficient mice
show reduced CD19 expression and overall B cell signal-
ing. In the absence of CD81 expression, CD19 expres-
sion is halved [11].
CD19 is thought to play duel roles in B cell activation.
First, it functions as an adaptor protein to recruit cyto-
plasmic signaling proteins to the membrane. Experi-
ments have shown that CD19 tyrosine residues are
phosphorylated. The tyrosine phosphorylated CD19 can
recruit SH2 domain–containing cytosolic proteins after
ligation with the BCR. The second role of CD19 is as a
signal subunit for the CD19/CD21 complex when colli-
gated with the BCR, where Ag bearing complement
enhances B-cell activation via BCR-CD19/CD21 coliga-
tion [4,12,21,27].
In addition, CD19 is involved with, though not essen-
tial, in the regulation of bone marrow development
through its actions on bone marrow cells via altering
BCR signals [12]. Others have proposed a critical role
for CD19 in the process of B cell development from
their early differentiation events in the bone marrow to
late maturation steps in the spleen [13]. In developing B
cells, CD19 is capable of modulating signal thresholds
independent of the BCR. In fact, CD19 signaling may
play a role in controlling the progression of early pre-B
to small, resting pre-B cells in the bone marrow by asso-
ciating with components of the pre-BCR.
CD19 transgenic mice (hCD19TG)
CD19 overexpression has been studied through use of
hCD19TG mice which express a human CD19 trans-
gene. Phenotypic analysis of hCD19TG mice show that
CD19 overexpression is associated with a dramatic
reduction (>80%) in the number of peripheral B cells,
primarily due to impaired generation and early develop-
ment of immature precursors in the bone marrow.
B cells of hCD19TG show a gene dosage dependent
increase in proliferation in response to mitogens such as
lipopolysaccharide (LPS), with homozygotes showing a
much more dramatic increases in proliferation than that
seen in CD19TG+/− heterozygous mice. B cells from
hCD19TG +/+ mice also showed higher background
proliferation, and survived longer than control cells in
culture without any mitogen stimulation.
Although hCD19TG mice have significantly reduced
numbers of peripheral B cells, they show an overall
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crease), but skewed responses of different immuno-
globulin isotypes: IgG2b levels increased by 168%, IgG3
levels decreased by 77%, and IgA levels remaining
relatively unchanged. CD19 overexpression therefore
increases B cell sensitivity to transmembrane signaling
and augments the overall susceptibility of B cells to
induced differentiation. The increase in B cell surface
receptor expression may feedback to inhibit the develop-
ment of bone marrow B precursors, linking overexpres-
sion to the observed decrease in peripheral B cells.
CD19 −/− mice
In contrast to hCD19TG mice, CD19 deficient mice is
associated with defects in later stages of B cell growth
and maturation that take place in the spleen and periph-
eral lymph tissues. CD19 deficiency had no significant
effect on the number of B cell precursor in the bone
marrow, nor on the size and morphology of B cells.
CD19−/− mice instead show dramatic reductions in the
total number and frequency of peripheral and splenic B
cells, especially of B1 cells, a B cell subtype found in the
peritoneal cavity that normally express higher IgM levels
than conventional B ( B2) cells, and low levels of IgD.
The B cells obtained from the peritoneum of CD19 −/−
mice predominantly expressed high levels of both IgM
and IgD.
The proliferative capacity of B cells in CD19 −/− mice
is consistently reduced in response to stimulation by a
range of LPS (mitogen) concentration, as well as in
response to antibody cross-linking of surface IgM. CD19
is not required for clonal expansion, and B cells in CD19
deficient mice are able to proliferate and differentiate
into plasma cells, albeit at reduced rates, consistent
across all mitogen concentrations tested.
Unlike the skewed response of Ig isotypes in
hCD19TG mice, levels of all immunoglobulin isotypes
were significantly reduced in the CD19 −/− mice. The
overall 77% reduction in Ig levels is primarily contribu-
ted to changes in the frequency of B cell differentiation,
not the decrease of peripheral B cell numbers. In par-
ticular, the dramatic reduction of IgG1 (86% decrease)
and IgG2a (84% decrease) hints that interactions be-
tween B cell and T cell, which facilitate these Ig isotypes,
are particularly affected in CD19 deficiency. The reduced
susceptibility to transmembrane signaling and lowered
rates of proliferation in CD19 −/− mice leads to decreased
formation of second follicles, germinal centers, and overall
reduced ability of effective humoral immunity in response
to T cell dependent antigen [28]. In CD19-deficient mice,
loss of splenic marginal zone B cells has been observed, as
well as significant deficiencies in specific peripheral B-cell
subsets [12,13]. Furthermore, since CD19 is important
both for B cell activation of T cell dependent antigen, aswell as for B cell maturation and memory cell selection,
mature CD19−/− B cells are profoundly deficient in
responding to antigens that require T-cell help [13,27].
Selectively silencing CD19 expression by siRNA knock-
down experiments leads not only to complete inhibition of
CD19-mediated calcium fluxes, but also a total halt in
CD38 signaling, without affecting the surface expression of
CD38 [24,25]. These data provide additional support that
CD19 is the main co-receptor in human B cells.
The critical importance has garnered CD19 the title of
being a rheostat – for its crucial roles in the normal
expansion and function of the peripheral B-cell pool [9].
It contributes to maintaining the balance between
humoral, antigen-induced response and tolerance induc-
tion, as even small modulations in CD19 expression can
impact B cell signaling thresholds and dramatically affect
the sensitivity and specificity of B cell mediated immun-
ity [14,28,29].
Disease association
The importance of CD19 can be seen through case stud-
ies as well as various studies of CD19-deficient mice.
CD19-deficient humans and mice exhibit hyporespon-
siveness to transmembrane signals, and weak T cell-
dependent humoral responses, leading to an overall
impaired humoral immune responses [9,17]. Homozy-
gous frame shift mutations of the cd19 gene have been
documented to result in truncation of the three key
cytoplasmic tyrosine residues. Patients with this type of
CD19 gene mutations showed normal numbers of pre-
cursor and total B cells, but decreased numbers of CD27
+ memory B cells and CD5+ B cells. Their B cells exhibit
normal levels of CD81 and CD225, but decreased CD21
and very low to undetectable CD19. The patients de-
velop hypogammaglobulinemia, showing impaired anti-
gen-induced BCR response and poor antibody response
to rabies vaccination, as well as increased susceptibility
to infection [18].
Studies showed that autoimmunity in CD19 transgenic
mice depends on MHC class II expression [19]. This led
to hypothesis that CD19 may play an important role in
in vivo modulation of MHC class II expression and
signaling. Such discoveries have led to mounting interest
in CD19 as a potential immunotherapy target for various
autoimmune disorders, including rheumatoid arthritis
and multiple sclerosis.
Though it is not known if CD19 contributes directly
to B cell carcinogenesis, its expression is highly con-
served on most B cell tumors [17]. It is expressed in
most acute lymphoblastic leukemias (ALL), chronic
lymphocytic leukemias (CLL) and B cell lymphomas
[30]. In fact, the majority of B cell malignancies express
CD19 at normal to high levels (80% of ALL, 88% of B
cell lymphomas and 100% of B cell leukemias) [9]. Other
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levels [31,32]. Although CD19 expression is observed in
normal plasma cells, malignant plasma (myeloma) cells
isolated from multiple myeloma patients have been
shown to lack CD19 expression, while isolates from pre-
myeloma patients show a mix of both CD19- and CD19
+ plasma cells [33]. CD19 levels can potentially be useful
as a diagnostic tool in distinguishing certain lymphoma
subtypes. Follicular lymphoma, for example, has lower
CD19 level more frequently than any other lymphoma
subtypes. Low CD19 is also more common in CD10-
positive than in CD10-negative diffuse large B cell
lymphoma (DLBCL) [31].
Interestingly, CD19, though a B cell hallmark, has also
been observed in cases of myeloid malignancies, includ-
ing in 2% of AML cases. Rare cases of CD 19-expressing
myeloblastic leukemia (AML-M2) in fact lack any mye-
loid surface antigens [34,35].
Recent studies have constructed one model of lympho-
magenesis involving CD19 and the proto-oncogene
c-Myc. A positive feedback pathway in which upregu-
lated CD19 expression and phosphorylation, induced by
constitutive c-Myc overexpression, serve to further pro-
mote and stabilize c-Myc signaling, whose downstream
effectors include important cell cycle regulators like
cyclin D2. Dysregulation in these regulators subsequently
enhance lymphomagenesis. Using transgenic c-Myc
mice, these studies have shown that CD19 expression,
although not required for the malignant transformation
in c-Myc–derived lymphomas, accelerates lymphoma-
genesis and is associated with increased disease severity.
On the other hand, c-myc transgenic mice with CD19
deficiency, as compared to those expressing CD19,
exhibited reduced malignancies and significantly higher
(>80%) increase in survival and life spans [17].
CD19 monoclonal antibodies for lymphoma and
leukemia therapy
CD19 monoclonal antibodies have been explored for
lymphoma therapy. Unconjugated mouse IgG2a anti-
CD19 monoclonal antibody (mAb) was studied in six
patients with progressive B cell lymphoma. The dosage
ranged from 225 mg to 1000 mg. Transient reduction of
tumor cells were seen. One patient achieved partial
remission twice [36]. Following the study, the mAb was
combined with interleukin-2 to treat 7 patients with
low grade lymphoma. More tumor cell reduction was
achieved in this study [37].
An immunotoxin conjugate of anti-B4-blocked ricin
(Anti-B4-bR) was studied as adjuvant therapy for
patients with B-cell non-Hodgkin's lymphoma (NHL) in
complete remission (CR) after autologous bone marrow
transplantation [38]. Forty-nine patients post-autologous
stem cell transplantation received the immunotoxin at adose of 30 microg/kg daily for 7 days by continuous i.v.
infusion.Thirty one patients received two or more
courses at 14-day intervals. The mean serum level on
day 7 with the first course was found to be 0.77+/−0.41
nM. Twenty three patients developed human antimouse
antibody and/or human anti-ricin antibody at a median
of 22 days from the initiation of Anti-B4-bR therapy
(range, 11–100 days).
A bi-specific T-cell engaging (BiTEW) antibody, blina-
tumomab, was engineered to direct cytotoxic T-cells to
B-cells expressing CD19. An open-label, multicenter,
single-arm, exploratory phase II trial was conducted to
evaluate efficacy and safety of BiTE in adult patients
with relapsed /refractory B-precursor ALL. Blinatumo-
mab was given at 15 μg/m2/day as continuous intraven-
ous infusion for 28-days followed by a 14-day rest. A
total of up to 5 cycles of blinatumomab treatment was
given to responding patients at one of three dose levels.
A total of 18 patients were enrolled at the last update in
2011. Twelve out of 18 patients (RR 67%) have achieved
a complete remission within the first 2 cycles. These
responders included 3 patients with t(4;11) and 1 patient
with Ph-positive B-precursor ALL. Four responders
proceeded to allogeneic HSCT. Major adverse events
included pyrexia, chills, disseminated intravascular co-
agulation /cytokine release syndrome leading to treat-
ment discontinuation, as well as fully reversible CNS
serious adverse events. Adding a cytoreductive pre-
phase and implementing a lower initial dosing at 5 μg/
m2/day in cohort 2a during the first week eliminated fur-
ther treatment discontinuations. There were no treat-
ment related deaths. A maintenance dose of 30μg/m2/
day in cohort 2b increased the number of adverse
events. Therefore, cohort 2a was selected for further
clinical development in this patient population [39].
SAR3419 (huB4-DM4) is a novel antibody-drug conju-
gate [40]. A humanized IgG1 anti-CD19 monoclonal
antibody was conjugated to a maytansine derivative
DM4 through a cleavable disulfide-bond linker [41].
DM4, the maytansine derivative, is a potent tubulin in-
hibitor, which is specifically directed to CD19-positive B
cells by the anti-CD19 mAb. A phase I, open-label,
dose-escalation study of SAR3419 as a single agent was
conducted as a first-in-human trial [42]. SAR3419 was
administered intravenously every three weeks for up to
six cycles to 39 patients with relapsed CD19+ B-cell
lymphoma. Dose levels ranged from 10 to 270 mg/m2.
The dose-limiting toxicities occurred in seven patients.
These included severe blurred vision associated with
microcystic epithelial corneal changes. The maximal tol-
erated dose (MTD) was 160 mg/ m2. Twenty-six patients
(74%) showed tumor response; six of those patients
achieved PR or CR. In particular, seven (47%) of 15
patients who had rituximab-refractory disease had tumor
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range of 3 to 7 days. Therefore, SAR3419 was shown to
have a safe profile when administered to patients with
relapsed B-cell lymphoma with the MTD at 160 mg/m2.
Conclusion and future directions
CD19 is a biomarker for B cells. CD19 functions as the
dominant signaling component of a multimolecular
complex on the surface of mature B cells, alongside
complement receptor CD21, and the tetraspanin mem-
brane protein CD81 (TAPA-1), as well as CD225. CD19
plays a critical role in maintaining the balance between
humoral, antigen-induced response and tolerance induc-
tion. Clinical development of CD19 monoclonal anti-
bodies, anti-B4-bR, BiTE, and SAR3419 (huB4-DM4) are
still in the early phase. It is forseeable that CD19 mAb
will be widely studied for therapies of lymphoma,
leukemia and autoimmune disorders. Through molecu-
larly engineered chimeric antigen receptor, CD19 direc-
ted immunotherapy for refractory CLL is promising
[43,44]. Further study in controlled trial with more
patients will be critical to validate this approach.
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